Spyre Therapeutics(SYRE)

Focus: Spyre Therapeutics is a public-stage biotechnology company focused on antibody-based therapeutics for immunology indications. The company is in early clinical development with a lean portfolio in Phase 1-2 trials.

Immunology

Profile data last refreshed 3h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

3-3 this month

Stable — net -3 jobs in 30d

1 added, 4 removed. Backfill posture.

Should You Work at Spyre Therapeutics?

AI assessment

Spyre is a speculative early-stage bet suitable only for scientists seeking platform ownership and equity upside; not for those prioritizing stability or near-term revenue validation.

Why Work Here

Antibody platform expertise in immunology offers deep technical specialization in a high-value modality.
Recently went public with $189M cash position (FY 2025), providing medium-term runway for early-stage programs.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

7 total

LOE Risk

Protected

No near-term cliffs

Hiring

Growing

Jobs increasing

Pipeline & Clinical Trials

SPY001-001

Healthy

PHASE_1

Clinical Trials (1)

NCT06448247A Study of SPY001-001 in Healthy Volunteers

Phase 1

Help build intelligence for Spyre Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Active hiring across Biometrics, QA, and TechOps signals operational buildout phase where early employees shape infrastructure.

Watch Out For

No marketed products and only $886K FY 2025 revenue; company is pre-commercial with existential dependency on pipeline success.
Multiple insider share sales (CEO, CMO, CFO) in June 2026 suggest leadership confidence erosion or pre-planned exits during volatile early trading.
Only 3 open roles and minimal headcount visibility; limited growth trajectory and compressed team means fewer advancement lanes.

Generated by Claude from Spyre Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

SPY002-091

Healthy

PHASE_1

Clinical Trials (1)

NCT06672718A Study of SPY002-091 in Healthy Volunteers

Phase 1

SPY003-207

Healthy

PHASE_1

Clinical Trials (1)

NCT06873724A Study of SPY003-207 in Healthy Volunteers

Phase 1

SPY002-072

Healthy

PHASE_1

Clinical Trials (1)

NCT06622070A Study of SPY002-072 in Healthy Volunteers

Phase 1

SPY001

Ulcerative Colitis

PHASE_2

Clinical Trials (2)

NCT07652294Long-term Safety and Efficacy of Multiple Long-acting Antibodies Alone and in Combinations for IBD

Phase 2

NCT07012395A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Phase 2

SPY002-072

Rheumatoid Arthritis

PHASE_2

Clinical Trials (1)

NCT07148414A Study of SPY072 in Rheumatic Disease

Phase 2

SPY072

Hidradenitis Suppurativa (HS)

Phase 2

Clinical Trials (1)

NCT07766005A Study of SPY072 in Adults With Moderate to Severe Hidradenitis Suppurativa (The SKYLIGHT Trial)

Phase 2

Interview Prep Quick Facts

Portfolio: 8 clinical trials

Top TAs: Immunology, Dermatology

Publications: 2 in PubMed

SEC Filings: 2 available

Open Roles: 3 active jobs

Therapeutic Area Focus

Immunology

3 pipeline

Dermatology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$886K62%

R&D Spend

$90M(10102%)53%

Net Income

-$339M

Hiring Trend

Stable

Open Roles

Added

-0

Filled/Removed

Based on last 4 crawl cycles

Research Publications(2)

Recent peer-reviewed publications with author affiliations at this company

Discovery, development, and characterization of SPY002 and SPY072, two novel extended half-life monoclonal antibodies targeting TL1A: in vitro properties, in vivo pharmacology, pharmacokinetics, and preclinical safety.

mAbs

2026

PMID:42106953

Stability of Protein Pharmaceuticals: Recent Advances.